Skip to main content

Advertisement

Table 1 Changes of primary tumor in patients with renal cell carcinoma before and at 12 weeks after neoadjuvant therapy

From: Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Variable Axitinib Sunitinib Sorafenib P 1 P 2 P 3
Maximal diameter (cm)a
 Before therapy 7.2 (6.2–8.5) 6.4 (5.7–10.3) 6.8 (5.8–11.0) 0.497 0.664 0.868
 After therapy 5.2 (4.4–7.4) 5.6 (5.1–9.8) 6.4 (4.8–6.4) 0.266 0.284 0.657
 Reduction 1.5 (1.2–2.2) 0.8 (0.5–1.1) 0.5 (0.4–0.8) 0.001 < 0.001 0.024
Reduction rate (%)a 22.4 (13.8–30) 12.2 (7.1–14.1) 6.9 (3.7–12.0) 0.001 0.001 0.023
> 10% reduction [cases (%)] 13 (86.7) 16 (66.7) 8 (26.7) 0.310* 0.001* 0.003*
  1. P1, axitinib vs. sunitinib; P2, axitinib vs. sorafenib; P3, sunitinib vs. sorafenib
  2. P, Wilcoxon signed-rank test; P*, Pearson’s Chi square test
  3. aThe data are presented as median (interquartile range)